Clinical trial
A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options
NCT00330473 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- May 31, 2008
- Enrollment
- 1,019 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.